Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
Rhea-AI Summary
Obagi Medical (NASDAQ: WALD) launched a two-step Lip Therapy protocol on February 3, 2026: Lip Therapy AHA + PHA Smoothing Micro-Peel ($55) and Soothe & Protect Lip Treatment SPF 30 ($40). The regimen pairs nightly chemical resurfacing with daily hydration and SPF to improve texture, hydration, and fine lines.
Products are available through professional channels now and on Obagi.com beginning February 3, 2026. Consumer perception testing reported immediate and two-week improvements in hydration and appearance.
Positive
- None.
Negative
- None.
News Market Reaction – WALD
On the day this news was published, WALD gained 5.26%, reflecting a notable positive market reaction. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $13M to the company's valuation, bringing the market cap to $256.08M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
WALD is up 4.97% with strong volume, while peers show mixed moves: EWCZ up 4.07%, ACU up 1.85%, DSY down 1.85%, and GROV/SKIN flat. The pattern points to a stock-specific response to the Obagi lip protocol launch rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | ALOHA collaboration | Positive | +13.5% | VIO Med Spa joins ALOHA Program to generate real‑world MagIQ evidence. |
| Jan 28 | ALOHA collaboration | Positive | -5.7% | Next Health collaboration to evaluate MagIQ in longevity-focused settings. |
| Jan 27 | ALOHA launch partner | Positive | -4.6% | Alpha Aesthetic Partners chosen as ALOHA launch partner for MagIQ rollout. |
| Jan 26 | ALOHA initial launch | Positive | +0.6% | Platinum Dermatology Partners selected for initial ALOHA real‑world program. |
| Jan 21 | ALOHA program debut | Positive | +6.9% | Launch of ALOHA Program and first FDA‑approved Obagi saypha MagIQ filler. |
Recent Obagi news has generally been positive, with stock reactions mixed: three aligned upside moves and two downside divergences following ALOHA/MagIQ updates.
Over the past weeks, Waldencast/Obagi has focused on launching and scaling Obagi® saypha® MagIQ™ via the ALOHA real‑world evidence program. Collaborations with Platinum Dermatology Partners, Alpha Aesthetic Partners, Next Health, and VIO Med Spa aimed to collect standardized clinical and patient-experience data across multiple sites. Price reactions ranged from modest gains to pullbacks, indicating variable investor response. Today’s lip therapy protocol launch extends Obagi’s professional-grade portfolio beyond injectables into targeted lip resurfacing and protection.
Market Pulse Summary
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with Waldencast’s pattern of investor interest in Obagi product and program launches, where several recent ALOHA/MagIQ announcements saw moves of up to 13.48%. However, prior news also produced downside divergences, underscoring that enthusiasm has not been uniform. With shares still 47.66% below the 52‑week high yet trading below the 2.11 200‑day MA, any sharp upside could face consolidation if momentum fades or execution expectations evolve.
Key Terms
glycolic acid medical
lactic acid medical
gluconolactone medical
hyaluronic acid medical
broad-spectrum medical
uva and uvb medical
AI-generated analysis. Not financial advice.
The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), continues its commitment to advanced skin science with the launch of two new lip innovations designed to work together as a targeted treatment protocol: Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30.
Building on the brand’s legacy of clinically backed solutions for skin health and rejuvenation, the new Lip Therapy protocol brings Obagi’s expertise to one of the most delicate areas of the face. Designed for nightly rejuvenation and daily protection, the two-step regimen gently resurfaces the lips while restoring hydration, improving texture, and defending against environmental stressors, including the sun’s UV rays.
“This exciting new launch reflects Obagi’s long-standing approach to skincare innovation,” said Justin Giouzepis, Chief Marketing Officer. “Thoughtful formulation and clinical validation come together in a dermatologist-tested lip protocol that delivers visible smoothing while remaining gentle enough for everyday use.”
The Lip Therapy AHA + PHA Smoothing Micro-Peel is a gentle no-scrub, chemical exfoliating treatment formulated with 3 resurfacing acids: Glycolic Acid, Lactic Acid, and Gluconolactone to resurface and smooth the delicate lip surface. Hyaluronic Acid, a multi-molecular glycerin system, and Argan Oil help lock in moisture and support a softer, smoother, more youthful-looking appearance. Designed as the first step in the regimen, the Micro-Peel visibly smooths texture and can help enhance the performance of subsequent treatments.
Following resurfacing, Soothe & Protect Lip Treatment SPF 30 delivers daily hydration, comfort, and broad-spectrum sun protection. Formulated with a plumping peptide complex, Calendula, Hyaluronic Acid, and Vitamin E, the treatment visibly smooths fine lines while supporting the lip barrier and protecting against UVA and UVB exposure. Its comforting, replenishing formula makes it ideal for everyday use.
In consumer perception testing, when used as part of the complete protocol, the vast majority of users reported their lips looked and felt smoother, plumper, and more replenished immediately after application, with continued improvements in hydration, fine lines, and overall lip appearance in just two weeks.1
“Lips are uniquely vulnerable to environmental damage and dehydration, especially following in-office treatments or the application of wrong topical products,” said Dr. Suzan Obagi, Chief Medical Director. “This two-step protocol addresses both rejuvenation and protection, helping patients maintain smoother, healthier-looking lips with clinically thoughtful ingredients they can trust.”
Together, the Lip Therapy AHA + PHA Smoothing Micro-Peel and Soothe & Protect Lip Treatment SPF 30 reinforce Obagi Medical’s philosophy that skin health is a long-term investment, extending targeted, professional-grade care to deliver visible, science-backed results where they matter most.
Lip Therapy AHA + PHA Smoothing Micro-Peel (
*Consumer perception study results on file. Results may vary.
1. Data on file at Obagi Cosmeceuticals LLC. Results may vary.
2. Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/424b9e84-977f-45a5-bb68-c9e06e9d6e29
